Drugs / LHW090
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01846468 | Mar 2013 → Jun 2014 | chronic kidney disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02678000 | Mar 2017 → Oct 2018 | chronic kidney disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02515331 | Nov 2015 → Aug 2017 | resistant hypertension | Novartis Pharmaceuticals | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LHW090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02515331 ↗ |
| Route | Oral | “Capsule - oral dose” NCT02515331 ↗ |